XML 33 R18.htm IDEA: XBRL DOCUMENT
v3.21.2

Collaborative Research and Development Agreements (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2021
Revenue Recognition [Abstract] |
Schedule of Milestones Achieved | Milestones recognized through June 30, 2021 under the GSK Agreement are as follows:
| Anti-PD-1 (JEMPERLI/Dostarlimab) |  | Anti-TIM-3 (GSK4069889A/Cobolimab) |  | Anti-LAG-3 (GSK40974386)
Milestone Event | Amount | Quarter Recognized |  | Amount | Quarter Recognized |  | Amount | Quarter Recognized
Initiated in vivo toxicology studies using good laboratory practices (GLPs) | $1.0M | Q2'15 |  | $1.0M | Q4'15 |  | $1.0M | Q3'16
IND clearance from the FDA | $4.0M | Q1'16 |  | $4.0M | Q2'16 |  | $4.0M | Q2'17
Phase 2 clinical trial initiation | $3.0M | Q2'17 |  | $3.0M | Q4'17 |  | $3.0M | Q4'19
Phase 3 clinical trial initiation - first indication | $5.0M | Q3'18 |  | — | — |  | — | —
Phase 3 clinical trial initiation - second indication | $5.0M | Q2'19 |  | — | — |  | — | —
Filing of the first BLA - first indication | $10.0M | Q1'20 |  | — | — |  | — | —
Filing of the first MAA - first indication | $5.0M | Q1'20 |  | — | — |  | — | —
Filing of the first BLA - second indication | $10.0M | Q1'21 |  | — | — |  | — | —
First BLA approval - first indication | $20.0M | Q2'21 |  | — | — |  | — | —
First MAA approval - first indication | $10.0M | Q2'21 |  | — | — |  | — | —
Milestones achieved through June 30, 2021 under the BMS Agreement are as follows:
| Anti-PD-1 (CC-90006)
Milestone Event | Amount | Quarter Recognized
Completion of first in vivo toxicology studies using GLPs | $0.5M | Q2'16
Phase 1 clinical trial initiation | $1.0M | Q4'16

X
- References No definition available. + Details
Name: | us-gaap_RevenueRecognitionAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration